Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Baird Maintains Outperform on bluebird bio, Lowers Price Target to $6

Author: Benzinga Newsdesk | August 15, 2024 06:58am
Baird analyst Jack Allen maintains bluebird bio (NASDAQ:BLUE) with a Outperform and lowers the price target from $7 to $6.

Posted In: BLUE

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist